![Spero Therapeutics, Inc. logo](/logos/SPRO.webp)
Spero Therapeutics, Inc.
NASDAQ:SPRO
Overview | Financials
Company Name | Spero Therapeutics, Inc. |
Symbol | SPRO |
Currency | USD |
Price | 1.315 |
Market Cap | 71,074,567 |
Dividend Yield | 0% |
52-week-range | 0.99 - 1.89 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Satyavrat Shukla C.F.A. |
Website | https://sperotherapeutics.com |
An error occurred while fetching data.
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD